Skip to main content
European Commission logo print header

A bioengineered, naturally-derived, sustainable biocide for breaking down organic biofilms formed by drug-resistant bacteria.

Objectif

Aequor's ABD (Aequor Biofilm Dispersant) represents a significant leap forward in the arms race between modern medicine and drug-resistant bacteria. The biofilm is the first line of defence for these drug-resistant microorganisms, a polymer-like structure of proteins and secretions that protects the colony from virtually everything but burning or scraping it away.

ABD does away with this problem in dramatic fashion. A natural biocidal agent derived from marine microorganisms, ABD is devastating for bacterial contamination, but gentle enough to be used as a supplement for antibiotic treatments. It is 99.99% effective at removing existing biofilms, prevents 99.99% of new biofilms from forming, and inhibits the growth of new bacterial colonies by over 92%. Lonza Group AG has verified this stellar performance in-vitro.

Aequor intends to use the funds from the SME instrument to study the EU and global market for biocides further, and to dig deeper into markets for antibiotic supplements. Further it will carry out growth projections and examine the process for clinical trials in-depth.

Appel à propositions

H2020-SMEInst-2016-2017

Voir d’autres projets de cet appel

Sous appel

H2020-SMEINST-1-2016-2017

Régime de financement

SME-1 - SME instrument phase 1

Coordinateur

AEQUOR LTD
Contribution nette de l'UE
€ 50 000,00
Adresse
72 GREAT SUFFOLK STREET
SE1 0BL LONDON
Royaume-Uni

Voir sur la carte

PME

L’entreprise s’est définie comme une PME (petite et moyenne entreprise) au moment de la signature de la convention de subvention.

Oui
Région
London Inner London — East Lewisham and Southwark
Type d’activité
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Liens
Coût total
€ 71 429,00